Why the study?
There is no direct evidence comparing apixaban and rivaroxaban for stroke prevention in nonvalvular atrial fibrillation, and a comprehensive evidence review across available network meta-analyses and real-world studies is lacking.
Does apixaban reduce major bleeding events compared to rivaroxaban in patients with nonvalvular atrial fibrillation?
Does apixaban reduce major bleeding events compared to rivaroxaban in patients with nonvalvular atrial fibrillation?
A systematic review of network meta-analyses and real-world evidence suggests apixaban has a lower risk of major bleeding compared to rivaroxaban in patients with nonvalvular atrial fibrillation, with similar efficacy.
Answers are grounded in this paper and cite their sources.
May support apixaban preference over rivaroxaban to limit bleeding in NVAF; extends observational data but low-certainty evidence leaves superiority unconfirmed.
There is no direct evidence comparing the 2 most commonly prescribed direct oral anticoagulants, apixaban and rivaroxaban, used for stroke prevention in nonvalvular atrial fibrillation (NVAF). A number of network meta-analyses (NMAs) of randomized control trials and real-world evidence (RWE) studies comparing the efficacy, effectiveness, and safety of apixaban and rivaroxaban have been published; however, a comprehensive evidence review across the available body of evidence is lacking. In this study, we aimed to systematically review and evaluate the clinical outcomes of apixaban and rivaroxaban using a combination of data gleaned from both NMAs and RWE studies. The review identified 21 NMAs and 5 RWE studies. The data demonstrated that apixaban was associated with fewer major bleeding events compared to rivaroxaban. There was no difference in the efficacy/effectiveness profiles between these treatments. Bleeding is a serious complication of anticoagulation therapy for the management of NVAF, and is associated with increased rates of hospitalization, morbidity, mortality, and health-care expenditure. The majority of studies in this comprehensive evidence review suggests that apixaban has a lower risk of major bleeding events compared to rivaroxaban in patients with NVAF.
No takes yet. Share an insight, caveat, or question.
Hill et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: